



<b>Contents</b>	<b>Page</b>
Intend to use.....	3
Summary and Explanation.....	3
Test Principle .....	3
Warnings and Precautions .....	4
Storage and Stability.....	5
Specimen Collection and Storage.....	5
Materials Supplied.....	6
Materials Required but not Supplied .....	7
Procedure Notes.....	7
Preparation of Component .....	8
Test Procedure.....	9
Interpretation of Results.....	10
References.....	11

	<b>SHIKARI® S-ATD</b>
	Denosumab (Prolia® ) antibodies qualitative analyse
Required Volume (µl)	10
Total Time (min)	140
Sample	Serum, plazma
Sample Number	96
Detection Limit (ng/mL)	+/-
Spike Recovery (%)	-
Shelf Life (year)	1

## Intended Use

The Matriks Biotek Antibody to denosumab (Prolia®) Enzyme-Linked-ImmunoSorbent-Assay (ELISA) Kit is intended for the qualitative determination of antibodies to denosumab (Prolia®) in serum and plasma. It is for professional use only.

## Summary and Explanation

According to the prospectus; denosumab (Prolia®) is indicated for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral, non-vertebral and hip fractures and to increase bone mass in men with osteoporosis at increased risk of fracture.<sup>1</sup> PROLIA is reimbursed for women and men aged 70 or over with a Bone Mineral Density (BMD) T-score of -2.5 or less.<sup>2</sup>

PROLIA has a mechanism of action unlike other osteoporosis treatments. Administered every six months as a subcutaneous injection, PROLIA is the only therapy that targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone). Through highly specific inhibition of RANK ligand, PROLIA decreases bone resorption, and improves bone density at all measured skeletal sites.

PROLIA is a twice-yearly injection under the skin, usually administered by a general practitioner or practice nurse, and works by targeting the cells that break down bone (osteoclasts) thereby making bone less susceptible to osteoporosis-related fractures.

Prolia binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.

## Test Principle

The Matriks Biotek Antibody to denosumab (Prolia®) ELISA is a sandwich assay for the determination of antibodies against denosumab in serum and plasma samples. During the first incubation period, antibodies to denosumab (ATD) in patient serum/ plasma samples are captured by the drug denosumab (Prolia®) coated on the wall of the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled specific conjugate is added to each well and then incubated.

After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction color is directly proportional to the concentration of ATD in sample.

## Warnings and Precautions

1. For professional use only.
2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
3. In case of severe damage of the kit package please contact Matriksbiotek or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
6. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
7. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
8. Avoid contact with Stop solution. It may cause skin irritations and burns.
9. Some reagents contain sodium azide ( $\text{NaN}_3$ ) as preservatives. In case of contact with eyes or skin, flush immediately with water.  $\text{NaN}_3$  may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with large volume of water to avoid azide build-up.
10. All reagents of this test kit containing human serum or plasma have been tested and were found negative for HIV I/II, HBsAg and HCV by FDA approved procedures. However, a presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.

## Storage and Stability

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The strips of microtiter plate is stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

## Specimen Collection and Storage

### Serum, Plasma (EDTA, Heparin)\*

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	-20°C	Keep away from heat or direct sun light
Stability:	7 d	6 mon	Avoid repeated freeze-thaw cycles

\*. Denosumab (Prolia®) infusion camouflages/masks the presence of antibody to denosumab (ATD) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATD. Matriks Biotek Laboratories propose to obtain blood sample just before the infusion of denosumab (Prolia®) or at least 2 weeks after the infusion of denosumab (Prolia®).

## Materials Supplied

1 x 12 x 8	MTP	<b>Microtiter Plate</b> Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with infliximab.
1 x 0.25 mL	RCTV CNTR	<b>Reactive Control</b> Ready-to-use. Contains denosumab -reactive reagent, human serum, stabilizers and <0.1% NaN <sub>3</sub>
1 x 0.5 mL	NEG CNTR	<b>Negative Control</b> Ready-to-use. Contains human serum, stabilizers and <0.1% NaN <sub>3</sub>
1 x 12 mL	ASSAY BUF	<b>Assay Buffer</b> Blue colored. Ready to use. Contains proteins, RF blockers and <0.1% NaN <sub>3</sub>
1 x 12 mL	POD CONJ	<b>Peroxidase Conjugate</b> Red colored. Ready to use. Contains peroxidase (POD) conjugate, RF blockers, stabilizer and preservatives.
1 x 12 mL	TMB SUBS	<b>TMB Substrate Solution</b> Ready to use. Contains TMB
1 x 12 mL	TMB STOP	<b>TMB Stop Solution</b> Ready to use. 1N HCl.
1 x 50 mL	WASHBUF CONC	<b>Wash Buffer, Concentrate (20x)</b> Contains Buffer with Tween 20.
2 x 1	ADH FILM	<b>Adhesive Film</b> For covering of Microtiter Plate during incubation.

## Materials Required but not Supplied

1. Micropipettes (< 3% CV) and tips to deliver 5-1000  $\mu\text{L}$ .
2. Bidistilled or deionised water
3. Calibrated measures.
4. Absorbent paper and timer.
5. Standard laboratory glass or plastic vials, cups, etc.
6. Wash bottle, automated or semi-automated microtiter plate washing system
7. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 620-690 nm is optional).

## Procedure Notes

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

## Preparation of Component

Dilute/ dissolve	Component	with	Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer*	Up to 200 mL	Bidist. water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	3 w

\*. Prepare Wash Buffer before starting assay procedure.



## Test Procedure

1	Pipette 100µl of Assay Buffer non-exceptionally into each of the wells to be used.
2	<p><b>QUALITATIVE ELISA TEST FORMAT</b></p> <p>Pipette 10 µL of ready-to use Cut-Off Serum, Reactive Control, and Samples into the respective wells of microtiter plate.</p> <p><u>Wells</u></p> <p>A1:                      Negative Control            B1:                      Negative Control            C1:                      Reactive Control            D1 and on.:            Sample (Serum/Plasma)</p>
3	Cover the plate with adhesive film. Briefly mix contents by gently shaking the plate. Incubate 60 min at room temperature (18-25°C).
4	Remove adhesive film. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
5	Pipette 100 µL of ready-to use Peroxidase Conjugate into each well.
6	Cover the plate with adhesive film. Incubate 60 min at room temperature (18- 25°C).
7	Remove adhesive film. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
8	Pipette 100 µL of TMB Substrate Solution into each well.
9	Incubate 20 min (without adhesive foil.) at room temperature (18-25°C) in the dark.
10	Stop the substrate reaction by adding 100 µL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow
11	Measure optical density with a photometer at 450 nm within 30 min after pipetting of the Stop Solution.

## Interpretation Of Results

For the run to be valid, the OD<sub>450/650</sub> nm of Positive Control should be  $\geq 1.00$  and the OD<sub>450/650</sub> nm of each Negative Control should be  $<0.200$ . If not, improper technique or reagent deterioration may be suspected and the run should be repeated.

The results are evaluated by a cut-off value which is estimated by multiplying the mean OD<sub>450/650</sub> nm of the negative controls by 3.

I.e.;

If "Sample OD<sub>450/650</sub>/the mean OD<sub>450/650</sub> of Negative Controls" is  $\geq 3$ , the sample is

**POSITIVE**

If "Sample OD<sub>450/650</sub>/the mean OD<sub>450/650</sub> of Negative Controls" is  $<3$ , the sample is  
**NEGATIVE**

## References

1. Amgen Product insert
2. Lewiecki EM. Denosumab--an emerging treatment for postmenopausal osteoporosis. *Expert Opin Biol Ther.* 2010; 10:467-76. [PubMed 20095877]
3. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med.* 2009; 361:756-65. [PubMed 19671655]
4. Food and Drug Administration. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices. 21 CFR Part 801. Final rule. (Docket No. 96N-0119) *Fed Regist.* 1998; 63:50660-704.
4. Food and Drug Administration. Latex-containing devices; user labeling. 21 CFR Part 801. Proposed rule. (Docket No. 96N-0119) *Fed Regist.* 1996; 61:32617-21.
5. Food and Drug Administration. Natural rubber-containing medical devices; user labeling. 21 CFR Part 801. Final rule. (Docket No. 96N-0119) *Fed Regist.* 1997; 62:51021-30.
6. Prolia™ (denosumab) injection risk evaluation and mitigation strategy (REMS). From FDA website. Accessed Nov 16, 2012.
7. Romas E. Clinical applications of RANK-ligand inhibition. *Intern Med J.* 2009; 39:110-6. [PubMed 19356186]
8. Rodriguez, RD, Sutjandra L, Peterson MC, et al. Population pharmacokinetic meta-analysis of denosumab in healthy and cancer subjects and postmenopausal women with osteopenia or osteoporosis. *The AAPS Journal.* 2009;11(S1).
9. Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. *J Bone Miner Res.* 2004; 19:1059-66. [PubMed 15176987]
10. Amgen. Prolia Postmarketing Active Safety Surveillance Program. Available at [www.proliasafety.com](http://www.proliasafety.com). Accessed August 26, 2010.
11. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. *J Pharm Sci.* 2004; 93:2645-68. [PubMed 15389672]
12. Food and Drug Administration Center for Drug Evaluation and Research. Summary review (application number 125320). From FDA website.
13. Amgen. Prolia (denosumab) injection medication guide. Thousand Oaks, CA. 2013 Jul.
14. Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med.* 2009; 361:745-55. [PubMed 19671656]
15. Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. *J Clin Oncol.* 2008; 26:4875-82. [PubMed 18725648]
16. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol.* 2010; 28:5132-9. [PubMed 21060033]
17. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol.* 2011; 29:1125-32. [PubMed 21343556]
18. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet.* 2011; 377:813-22. [PubMed 21353695]